Mar. 17 at 8:56 PM
$XOMA Xoma reports Q4 net loss
$4M vs net loss
$20.1M last year
Reports Q4 revenue
$1.8M.Tom Burns, Chief Financial Officer of XOMA Royalty, commented, "Based upon the anticipated incoming cash payments from royalties alone, we have line of sight on becoming cash flow positive on a consistent basis. The transient expenses associated with the Kinnate and Pulmokine acquisitions that impacted our 2024 financial results are coming to a close. We expect our R&D and G&A expenses to normalize in the second half of 2025." Income and Revenue: XOMA Royalty recorded total income and revenues of
$8.7M and
$28.5 million for the fourth quarter and full year of 2024, respectively.
In 2023, XOMA Royalty recorded total income and revenues of
$1.8 M and
$4.8 million for the fourth quarter and full year, respectively. The increase for the full year of 2024 was primarily driven by an increase in our income from purchased receivables. "Our growing commercial royalty portfolio of six assets is supported by VABYSMO JEMDA and MIPLYFFA while our Phase 3 portfolio, which now totals 11 assets, promises several key readouts in 2025, including ersodetug from Rezolute, seralutinib from Gossamer Bio, and Ovaprene from Dare Biosciences. With over
$100M in cash on hand and a clear path to sustainable cashflow from royalties alone, we are well-positioned to further our goal of driving value for patients and shareholders alike."
